N-Power Medicine, a provider of a platform for clinical trials, has raised an undisclosed sum in a Series B funding round led by Merck Global Health Innovation Fund, with participation from a US-based healthcare-focused investor. This brings the total funds raised by the company to USD 72 million.
The raised funds will be used to expand N-Power's oncology clinic network. By year-end, N-Power plans to partner with six to eight oncology clinics and expects to have more than 100 oncologists in its network.
In addition to the funding, N-Power partnered with Merck to expand access to clinical trials for oncologists and patients. Through the partnership, Merck's clinical trials will be available across N-Power’s network sites, with two initial trials currently available.
Based in California, N-Power Medicine focuses on transforming clinical trials in oncology through its purpose-built clinical research platform. The company's main offering, the N-Power Platform, aims to accelerate drug development by enabling community oncology practices to conduct clinical trials more effectively by integrating research and standard care into a single workflow. N-Power additionally provides on-site and virtual staffing to support clinical research operations.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.